LEXINGTON, Mass., Oct 28, 2016 — CBSET Inc. announced today that it has appointed Dr. Rami Tzafriri as Director of Research and Innovation. Since 2009, Dr. Tzafriri has held the position of Principal Scientist at CBSET, where he developed quantitative computational and experimental methods for evaluating combination drug and energy delivery devices. He is best known […]
Category Archives: News
Press Release: CBSET appoints Michael Naimark as Director of Business Development
LEXINGTON, Mass., Oct 27, 2016 — CBSET, Inc. announced today that it has appointed Michael Naimark as Director of Business Development, effective immediately. Most recently, he was employed by the Neural Stem Cell Institute (NSCI) as project manager overseeing the development of a cell-based therapy for macular degeneration under a 4-year award from the New York Stem […]
News Advisory: You Need To Know: Endovascular Drug Delivery Is Experiencing a Resurgence in Innovation
“Understanding and computationally modeling the determinants of drug release kinetics and tissue distribution can help further drive innovation at reduced cost.” – Rami Tzafriri, PhD, Principal Scientist, CBSET “Endovascular Drug Delivery and Drug Elution Systems: First Principles” Abraham Rami Tzafriri, PhD Elazer Reuven Edelman, MD, PhD “…The first principles outlined…serve as a handbook for features […]
Press Release: A Paradigm for Safety Assessment of Energy-Based Devices: CBSET Presents In Vivo Data at SoT 2016
“We have developed a preclinical paradigm for predictably modulating the efficacy of thermal ablation devices while minimizing adverse effects on target and surrounding tissues,” said Dr. John H. Keating, Director of Pathology, CBSET. LEXINGTON, Mass., March 10, 2016 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical […]
Press Release: MANTA Vascular Closure Device Safely and Effectively Closes Large Bore Arterial Access Sites: CBSET to Present Preclinical Data at ICI 2015
“Vascular access complications are a significant source of morbidity, especially for interventions such as TAVR that require large bore cannulation,” said Haim Danenberg, M.D., CBSET’s chief scientific advisor. “CBSET’s study demonstrates that MANTA is a safe and reliable large-bore percutaneous closure device.” LEXINGTON, Mass., Dec. 10, 2015 — Scientists at CBSET, a not-for-profit preclinical research […]
Press Release: Data provides new insights into the optimal balance between drug-eluting stent coating material properties and drug elution kinetics
“Drug eluting stents remain a ripe field for continued innovation. Until now, the focus on sustainable drug elution has strictly limited the choice of DES coating materials. Our study results confirm a new paradigm for optimizing coating biocompatibility,” said Rami Tzafriri, PhD, Principal Scientist, CBSET. LEXINGTON, Mass., Oct. 28, 2015 — CBSET, a not-for-profit preclinical […]
Press Release: Primary lesion treatment using Diamondback 360® orbital atherectomy system enhances paclitaxel deposition in calcified peripheral arteries: preclinical data presented at EuroPCR 2015
““This preclinical study could have a significant clinical impact by demonstrating improved drug delivery after modification of calcified lesions,” said Gunnar Tepe, M.D., RoMed Hospital, Rosenheim, Germany. LEXINGTON, Mass., May 20, 2015 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed today that modification of atherosclerotic […]
Endovascular Today: Preclinical Study Evaluates Primary Lesion Treatment With CSI’s Orbital Atherectomy System Before Drug Delivery in Calcified PAD
May 20, 2015—CBSET, a preclinical biomedical research institute, announced findings from a cadaver study suggesting that modification of atherosclerotic plaque with the Diamondback 360 orbital atherectomy system (Cardiovascular Systems, Inc. [CSI]) improved drug uptake in calcified peripheral lesions. Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, stated in CBSET’s announcement, “This preclinical study could have a significant […]
Press Release: Roadmap for the revitalization of catheter-based renal sympathetic denervation related to clinically meaningful, optimized device design: CBSET to present compelling preclinical evidence at EuroPCR 2015
“Renal denervation, despite recent stumbles, is experiencing a resurgence with next-generation device design. CBSET’s incontrovertible mechanistic data provides the pathway for predicting efficacy and designing more efficacious devices and protocols,” said Peter M. Markham, President and CEO, CBSET. LEXINGTON, Mass., May 18, 2015 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, […]
Press Release: Variable patient responses to catheter-based renal denervation therapy is explained by local tissue anatomy – suggesting a paradigm for treatment optimization: CBSET data published in Science Translational Medicine
“The combination of both preclinical experiments and computational models is necessary to understand the basis of clinical efficacy: variation in ablation zone geometry caused by diversity in local tissue anatomy,” said Peter M. Markham, President and CEO, CBSET. LEXINGTON, Mass., May 4, 2015 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and […]